Lu Alleruzzo, CEO and David Anderson, PhD, CSO of Immunophotonics, are excited to participate in the NCI SBIR Peer Learning and Networking (PLAN) webinar series. On Tuesday, November 19, from 3 PM to 4:30 PM (CST), they will share their insights and expertise in the session titled “CEO Perspectives on Launching & Growing Biotech Start-ups.”...
Immunophotonics co-founders Lu Alleruzzo, CEO and Tomas Hode, PhD, CIO, and President will attend the AngioDynamics International Life Symposium taking place November 7th to 9th in Monte Carlo. They will engage with industry partners and clinical experts globally, focusing on the latest breakthrough technologies for surgical interventions. Look for Lu and Tomas at this event...
Congratulations to Professor Wei Chen and his lab University of Oklahoma for their publication titled “Localized ablative immunotherapy enhances antitumor immunity by modulating the transcriptome of tumor-infiltrating Gamma delta T cells” in Elsevier Cancer Letters an international journal providing a forum for original and significant contributions in cancer research. Click here to read the publication
Siu Kit “Samuel” Lam, PhD, Senior Vice President of Science & Research at Immunophotonics, Inc. attended the SITC Immuno-Oncology Drug Development Summit held in Boston from September 30 – October 1, 2024. The program was highly informative, offering valuable insights, essential resources, and best practices for the development of immuno-oncology therapeutics. It also provided opportunities...
Immunophotonics wants to congratulate Professor Wei Chen and his lab University of Oklahoma, along with contributors Lu Alleruzzo, Samuel S.K. Lam, Tomas Hode, David Anderson, Johnny Wong, Abby Delawder, Joe Raker of Immunophotonics, for their publication titled “N-dihydrogalactochitosan Drives Conventional and Alternative Activations of STING to Synergize Type I IFN and IL-1β Productions of Antitumor...
Immunophotonics is pioneering the field of Interventional Immunology-Oncology™, where a single injection of IP-001 –seamlessly integrated into the clinical workflow– has the potential to transform a routine tumor ablation into a systemic immunotherapy to fight cancer throughout the body. Immunophotonics co-founders Lu Alleruzzo, CEO and Tomas Hode, PhD, CIO, and President are pleased to announce...
Immunophotonics co-founders Lu Alleruzzo (CEO), Tomas Hode, PhD (CIO and President), and David Anderson, PhD (CSO) are excited to be attending CIRSE 2024 Congress taking place in Lisbon, Portugal, September 14th to 18th and ESMO Congress in Barcelona, Spain on September 16th. They look forward to engaging with fellow professionals, discussing the latest advancement in...
Immunophotonics won the Startup World Cup St. Louis Regional finals. A big thank you to Emily Hemingway and her team at TechSTL for their hard work in organizing this remarkable event. You did an exceptional job! We also want to extend our gratitude to the judges—Vikram Lakhwara, Atul Kamra, Rick Holton Jr., and Julia Campbell—for...
We are thrilled to announce that Dr. Robert Martin has successfully enrolled and treated the first patient in our groundbreaking clinical trial: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of IP-001 as Adjuvant Therapy in Participants with Hepatocellular Carcinoma after Complete Radiological Response following Surgical Resection and Local Ablation or Local...
Immunophotonics is excited to share that Wei Chen, co-inventor of IP-001, Stephenson Chair, professor and interim director of the Stephenson School of Biomedical Engineering and his team recently organized a session titled “Immunophotonics” for the Gordon Research Conference Optics and Photonics in Medicine and Biology in Lewiston, Maine. During this session, Professor Chen delivered an...
